Iopidine

Apraclonidine Hydrochloride, the active ingredient in Iopidine, is a alpha-2 adrenergic agonist presented as an ophthalmic solution for ocular use. It reduces intraocular pressure and is used in the management of glaucoma and ocular hypertension.

GNH USA supplies Iopidine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iopidine is an alpha-2 adrenergic agonist indicated for conditions that require lowering of intraocular pressure. - Glaucoma: helps lower elevated intraocular pressure to prevent optic nerve damage. - Ocular hypertension: reduces pressure in eyes without established glaucomatous damage. - Reduction of intraocular pressure: provides adjunctive control when monotherapy is insufficient.

Iopidine may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Burning or stinging sensation on instillation. - Ocular hyperemia (redness). - Blurred vision. - Conjunctival irritation. - Mild allergic conjunctivitis.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis). - Persistent ocular inflammation or uveitis. - Systemic hypotension leading to dizziness. - Corneal edema. - Vision loss (very rare).

Before using Iopidine, consider the following safety measures. - Monitor intraocular pressure: assess response and adjust therapy as needed. - Cardiovascular disease: use with caution in patients prone to hypotension. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Concomitant ocular drugs: avoid using with other alpha‑2 agonist eye drops without professional guidance. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at room temperature: keep in the original container, protect from light and moisture.

Iopidine can interact with other medications that affect ocular pressure or systemic blood pressure.

Major Interactions (Avoid): - Other alpha‑2 adrenergic ophthalmic agents: additive ocular hypotensive effect may cause excessive pressure drop. - Systemic antihypertensives (e.g., beta‑blockers, ACE inhibitors): risk of systemic hypotension.

Moderate Interactions (Monitor Closely): - Topical beta‑blocker eye drops: may enhance intraocular pressure reduction. - Cycloplegic agents: could alter pupil dynamics and affect drug distribution. - Non‑steroidal anti‑inflammatory eye drops: may increase risk of ocular irritation.